Genus (LON:GNS) Stock Passes Above 200 Day Moving Average of $4,662.17

Genus plc (LON:GNS) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 4,662.17 ($60.91) and traded as high as GBX 5,190 ($67.81). Genus shares last traded at GBX 4,972 ($64.96), with a volume of 83,400 shares traded.

Separately, Liberum Capital boosted their price target on Genus from GBX 4,490 ($58.66) to GBX 4,760 ($62.19) and gave the stock a “buy” rating in a research note on Monday, January 18th.

The firm has a market capitalization of £3.25 billion and a P/E ratio of 67.55. The business has a fifty day moving average of GBX 5,076.46 and a 200-day moving average of GBX 4,662.17. The company has a debt-to-equity ratio of 28.59, a quick ratio of 1.26 and a current ratio of 1.86.

The company also recently declared a dividend, which was paid on Thursday, April 1st. Shareholders of record on Thursday, March 4th were paid a dividend of GBX 10.30 ($0.13) per share. This represents a yield of 2.06%. The ex-dividend date of this dividend was Thursday, March 4th. Genus’s payout ratio is currently 0.40%.

In related news, insider Iain Ferguson acquired 500 shares of the business’s stock in a transaction dated Thursday, February 25th. The stock was bought at an average price of GBX 4,851 ($63.38) per share, for a total transaction of £24,255 ($31,689.31). Over the last ninety days, insiders have acquired 1,003 shares of company stock valued at $4,840,680.

Genus Company Profile (LON:GNS)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.

Further Reading: How a Strangle Strategy is different from a Straddle Strategy

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit